DAIICHI-SANKYO-EUROPE
8.12.2022 08:01:35 CET | Business Wire | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today that the primary endpoint was met in the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial, demonstrating statistically significant relative risk reduction in major adverse CV events (MACE-4) in patients treated with 180 mg/day bempedoic acid compared to placebo (with no or very low statin background).1,3
Comprehensive data from the CLEAR Outcomes Trial, led by US-based biotech company Esperion Therapeutics Inc., will be presented at a key medical congress in early 2023 and subsequently submitted to applicable regulatory authorities. The initial findings from the data indicate that bempedoic acid is the first oral, ACL inhibitor known to reduce both LDL-C levels and risk of major adverse CV events.1 The findings are congruent with previous significant evidence and the latest clinical guidelines highlighting that the lower a person’s LDL-C level, the lower their cardiovascular risk.4
“The positive results from the CLEAR Outcomes Trial represents a pivotal step towards reducing the impact of CVD in Europe for patients who are currently at high risk of heart attack and stroke,” said Professor Kausik Ray, Professor of Public Health and President of the European Atherosclerosis Society, Honorary Consultant Cardiologist, Director ICTU Global and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London. “I am very excited to see more data from the trial over the coming months and better understand how bempedoic acid can continue to help clinicians bring LDL-C levels of patients to guideline-recommended goals and thus reduce the impact of cholesterol on CV health in Europe.”
“With 10,000 lives lost everyday to CVD in Europe, we are truly encouraged by this new data, which demonstrates that bempedoic acid does reduce the risk of serious CV events for patients who are at high-risk of experiencing a heart attack or stroke,”1,4 said Dr Stefan Seyfried, Vice President Medical Affairs Specialty Medicines, Daiichi Sankyo Europe GmbH. “We look forward to sharing additional analyses and insights, as well as working closely with the scientific and clinical communities, to better understand how the data can support their care for CVD patients across Europe.”
CLEAR Outcomes was a Phase 3, event-driven, randomised, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduced the risk of CV events in patients with or who are at high risk for ASCVD with documented statin intolerance and elevated LDL-C levels (fasting blood LDL-C ≥ 100 mg/dL (2.6 mmol/L)).3 The study, which was fully enrolled in August 2019, included 14,014 patients at over 1,200 sites in 32 countries. Patients had at least 36 months of follow-up.3
-ENDS-
About bempedoic acid
Bempedoic acid (commercialised in the European Economic Area, Turkey and Switzerland as NILEMDO®▼) is a first-in-class, oral treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.2,5 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.2
Bempedoic acid has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies. Due to its unique mechanism of action, bempedoic acid is not activated in skeletal muscle.
Daiichi Sankyo Europe has licensed exclusive commercialisation rights to bempedoic acid in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realise our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”
For more information, please visit www.daiichisankyo.com
▼ This medicinal product is subject to additional monitoring.
____________________________________________________
2 European Medicines Agency. NILEMDO Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf. Last accessed December 2022.
3 Nicholls, S.J., et.al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021. 235: 104–112.
4 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemia. Eur Heart J. 2020. 41(1):111–188.
5 SwissMedic. NILEMDO (bempedoic acid) Product Information for Human Medicinal Products. Available at: https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-nilemdo.html. Last accessed December 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005816/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi’s 2026 State of Mathematical Optimization Report Reveals Growing Convergence of AI and Optimization28.10.2026 14:00:00 CET | Press release
Survey finds GenAI use is on the rise as organizations embed optimization deeper into everyday operations. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of its 2026 State of Mathematical Optimization Report. Based on a survey of 382 non-academic professionals across industries, the report examines how businesses are putting optimization to work, and how its use is evolving alongside other AI technologies. In a notable shift, 79% of respondents now use GenAI or large language models (LLMs) in their optimization work, up from 30% in 2025, with 37% using these tools systematically in their development workflows. Respondents see the greatest potential for this combined approach in code generation and debugging (68%), model formulation (67%), and natural-language interaction with optimization models (62%). Other key findings include: Optimization is becoming part of everyday operations: 52% of respondents say optimization supports ongo
1GLOBAL Empowers WEtell to Offer Sustainable Global Travel Connectivity28.10.2026 14:00:00 CET | Press release
New partnership integrates 1GLOBAL's eSIM infrastructure into WEtell's digital platform, bringing travel connectivity to every WEtell customerCustomers can activate global data plans in seconds without physical SIM cards, roaming complexity, or long-term commitments 1GLOBAL, a pioneer in global telecommunications solutions, today announced a new partnership with climate-neutral mobile phone provider WEtell to bring sustainable, app-based travel connectivity to its customers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028932032/en/ The partnership integrates 1GLOBAL's eSIM infrastructure into WEtell's digital platform, delivering sustainable global travel connectivity to WEtell customers. WEtell, founded in Freiburg in 2019, focuses on sustainable mobile communication, with an ethos of promoting eco-conscious consumption and integrating environmental and social values into its mobile services. When WEtell use
Wolters Kluwer names Tomàs Font General Manager of Corporate Tax28.10.2026 14:00:00 CET | Press release
Experienced Wolters Kluwer executive to lead Corporate Tax as business expands its global indirect tax capabilities Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the appointment of Tomàs Font as General Manager of its Corporate Tax business, part of the Corporate Performance & ESG division. Wolters Kluwer is expanding its support for corporate tax departments and building a more complete indirect tax offering to serve a broader market of multinational organizations. The recent acquisition of Marosa, a provider of VAT compliance and e-invoicing solutions, adds those capabilities to Wolters Kluwer’s established CCH SureTax U.S. sales and use tax offering. Planned VAT Determination capabilities will further extend the offering, supporting Wolters Kluwer’s expansion into the global indirect tax market. “As we build a more complete indirect tax offering for multinational customers, our ambition for this business has grown consi
Cognite Reports $1 Billion in Verified AI Value, Confirming Impact of Industrial AI Solutions28.10.2026 14:00:00 CET | Press release
One year after launching its $100B Moonshot, Cognite reaches major milestone, challenging traditional enterprise software metrics by focusing on bottom-line customer ROI Cognite, the global leader in Industrial AI, today announced that companies using its Industrial AI and Data Platform have unlocked more than $1 billion in verified, realized value. The milestone comes exactly one year after the company publicly announced its 10-year Moonshot at its customer conference—a strategic commitment to deliver $100 billion in quantifiable value to Cognite customers by 2035. While no other Industrial AI vendor has made such a commitment, Cognite believes aligning its own success metrics with how customers measure real-world impact is an important distinction that builds greater trust and mutual success. "Documenting $1 billion in verified value in just twelve months is a testament to the deep collaboration among our customers, partners, and the internal teams at Cognite that support them," said
Sparxity Announces Multi-Million-Dollar Sparse-Native Computing Deployment at the Jülich Supercomputing Centre28.10.2026 14:00:00 CET | Press release
Formerly SpiNNcloud, the company has also announced a strategic rebrand to Sparxity, supporting its vision to only compute what matters Sparxity (formerly SpiNNcloud), a leader in sparse-native computing, today announced the deployment of its sparse-native computing rack system at the Jülich Supercomputing Centre (JSC), one of Europe’s largest supercomputing research centers and an institute of Forschungszentrum Jülich. The multi-million-dollar installation at JSC is built on Sparxity’s sparse-native systems for HPC and AI and will be utilized for running sparse machine learning models and large-scale HPC simulations. This implementation validates Sparxity’s vision to only compute what matters and coincides with the launch of its new brand identity, opening a new world of compute built on sparsity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028075211/en/ JSC is the home of Europe’s first exascale supercomputer and is
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom